论文信息 - Malignant melanoma during ustekinumab therapy of Crohn's disease. - 字舞流文

Malignant melanoma during ustekinumab therapy of Crohn's disease.

S. Brand | A. Wollenberg | L. Ehmann | C. Tillack-Schreiber

[1] M. Kappelman,et al. Nonmelanoma skin cancer in inflammatory bowel disease: A review , 2011, Inflammatory bowel diseases.

[2] G. Greenberg,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial , 2011 .

[3] S. Brand,et al. Risk Of Malignancies In A Single Center Cohort Of IBD-Patients Treated with Immunosuppressives and Anti-TNF-antibodies , 2011 .

[4] E. Scherl,et al. Review of the safety and efficacy of ustekinumab , 2010, Therapeutic advances in gastroenterology.

[5] A. Marghoob,et al. Defining the patient at high risk for melanoma , 2010, International journal of dermatology.

[6] M. Schaller,et al. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. , 2009, Melanoma research.

[7] C. Elmets,et al. Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors. , 2007, Cancer research.

[8] S. Beissert,et al. Enhanced photocarcinogenesis in interleukin-12-deficient mice. , 2006, Cancer research.